Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01218477 · ClinicalTrials.gov registry record · Phase 1
Dasatinib Combination Therapy With the Smoothened (SMO) Inhibitor BMS-833923 in Chronic Myeloid Leukemia (CML)
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
NCT01218477 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 33 participants.
The verdict
NCT01218477, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
The purpose of the study is to determine the safety and tolerability of the combination of BMS-833923 plus dasatinib in patients with chronic myeloid leukemia.
Interventions
- DRUG Dasatinib
- DRUG BMS-833923
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2011-01 |
| Est. Completion | 2013-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01218477
The ClinicalTrials.gov registry entry for NCT01218477 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Dasatinib is the first listed.
NCT01218477 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01218477 about?
NCT01218477 is a clinical study titled "Dasatinib Combination Therapy With the Smoothened (SMO) Inhibitor BMS-833923 in Chronic Myeloid Leukemia (CML)". The purpose of the study is to determine the safety and tolerability of the combination of BMS-833923 plus dasatinib in patients with chronic myeloid leukemia.
What is the current status of trial NCT01218477?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2011-01. Estimated completion is 2013-04.
What interventions are being tested in trial NCT01218477?
The interventions under investigation include: Dasatinib (DRUG), BMS-833923 (DRUG).
Who is sponsoring clinical trial NCT01218477?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.